ClinicalTrials.gg
CompletedNCT04773678Updated Mar 29, 2024

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

A Phase 2 interventional study of CBP-201 and Placebo in Moderate to Severe Persistent Asthma, sponsored by Connect Biopharm LLC. Completed at 76 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-29.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
371st of 1,353
322 · median 100
Started
2021
with 72 others
Phase 2
292 of 1,695
22 open now
Registered
1,403rd of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 371st largest by enrollment of the 1,353 interventional ones that give a count, is one of 73 that started in 2021, is one of 292 in phase 2, and was the 1,403rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.

Read the detailed description

This is a multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy and safety of two dose levels of CBP-201 administered to eligible patients with moderate to severe persistent asthma with Type 2 inflammation compared to placebo. CBP-201 is administered as a subcutaneous (SC) injection. The study is divided into a treatment period of 24 weeks and a follow-up period of 8 weeks.

03

Conditions studied

  • Moderate to Severe Persistent Asthma

Browse trials for

Keywords

  • Type 2 inflammation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male or female patient aged 18 to 75 years with a physician diagnosis of asthma for a minimum of 12 months, based on the Global Initiative for Asthma (GINA) 2020 Guidelines.
  2. Patient is currently receiving treatment with medium to high dose inhaled (ICS) in combination with at least 1 additional reliever/controller for at least 90 days prior to the Screening Visit with a stable dose of ICS at least 28 days prior to the Screening Visit.

    Note:

    • Patients receiving ICS equivalent to ≥ 226 μg fluticasone propionate twice daily or equipotent ICS daily dosage of a maximum of 2000 μg/day fluticasone propionate (or equivalent) in combination with a second reliever/controller (eg, long-acting ß agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], theophylline) are eligible.
    • Patients receiving fluticasone furoate/vilanterol with fluticasone furoate ≥ 200 μg once daily are eligible.
    • Patients receiving budesonide/formoterol with budesonide ≥ 640 μg/day are eligible.
    • Patients requiring a third reliever/controller for their asthma are eligible.
    • Patients requiring maintenance oral corticosteroids (OCS) with a stable dose ≤ 10 mg/day prednisone or equivalent OCS in addition to ICS are eligible; OCS total daily dose must have been stable at least 28 days prior to Screening.
  3. Prebronchodilator (trough) of expiration (FEV1) must be 40 to 85% of predicted normal at Screening and predose Baseline.
  4. Patients must have ≥ 12% reversibility (and ≥ 200 mL difference) in FEV1 within 15 to 30 minutes after the administration of up to 4 puffs of albuterol/salbutamol at Screening.
  5. Blood eosinophil count ≥ 300 cells/μL at Screening.
  6. Asthma Control Questionnaire, 6-question (ACQ-6) score ≥ 1.5 at Screening and Baseline.
  7. Patient has experienced an asthma exacerbation at least once in the past 12 months, defined here as:

    • Use of physician prescribed systemic corticosteroid [oral or parenteral], or
    • Asthma requiring treatment increase of approximately 4 times the baseline dose of ICS, or
    • Hospitalization or emergency medical care due to asthma.
  8. Patient demonstrates acceptable inhaler, peak flow meter, and spirometry techniques during the Screening Period in the opinion of the Investigator.
  9. Patient demonstrates at least 70% compliance with usual asthma controller use during Run-in Period, based on their patient diary in the 7 days prior to dosing.
  10. Patient demonstrates at least 70% compliance with recording of symptom scores in the patient-reported outcomes (PRO) diary completion during Run-in Period and in their handheld pulmonary function device in the 7 days prior to dosing.
  11. Patient is able to understand and willing to sign the form (ICF).
  12. Patient is willing and able to comply with clinic visit schedule and study-related procedures, in the opinion of the Investigator.
  13. Male patients and their female partners of agree to practice adequate and effective forms of through the duration of the study from first dose to 8 weeks after the last dose of study drug.
  14. Female patients of childbearing potential who are sexually active with a non-sterilized male partner agree to practice adequate and effective forms of contraception from first dose to 8 weeks after last dose of study drug.

Exclusion criteria

Exclusion Criteria:

-

A patient who meets any of the following criteria will be ineligible to participate in this study:

  1. Patient has a current diagnosis of a respiratory disorder other than asthma (eg, active lung infection, (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis) or other disease associated with elevated peripheral eosinophil counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
  2. Patient has an acute upper or lower respiratory infection requiring antibiotics or antiviral medication within 30 days prior to the date of or during the Screening/Run-in Period. Note: Patients must be symptom-free for at least 30 days.
  3. Patient experiences ana asthma exacerbation at any time from 1 month prior to the Screening Visit up to and including the Baseline Visit. Exacerbation is defined as:

    • Use of physician prescribed systemic [oral or parenteral], or
    • Asthma requiring treatment increase of approximately 4 times the baseline dose of ICS, or
    • Hospitalization or emergency medical care due to asthma.
  4. Current smoker or former smoker with a smoking history of > 10 pack-years. Note: This includes tobacco, marijuana, and vaping products.
  5. Patient is undergoing or planning to undergo any elective surgery during the study requiring general anesthesia.
  6. Patient has received treatment with any marketed (eg, omalizumab, benralizumab, mepolizumab, reslizumab, dupilumab) or biologic drug for asthma or other diseases within 16 weeks or 5 half-lives prior to randomization, whichever is longer.
  7. Patient has received treatment with any investigational nonbiologic drug within 30 days or 5 half-lives prior to randomization, whichever is longer.
  8. Patient did not respond favorably to previous dupilumab treatment (e.g. therapy failure or patient experienced an adverse reaction to treatment).
  9. Patient has received specific immunotherapy within 3 months prior to randomization. Note: If the patient has received immunotherapy, a 3 month is required following the last dose of immunotherapy.
  10. Patient is receiving medications or therapy that are prohibited as concomitant medications.
  11. Patient has a known or suspected history of , including history of invasive opportunistic infections, such as aspergillosis, coccidioidomycosis, histoplasmosis, , listeriosis, pneumocystosis, pulmonary non-tuberculosis mycobacteria, or tuberculosis, regardless of infection resolution; or unusually frequent, recurrent, or prolonged infections. Note: Tuberculosis testing will be performed on a country-by-country basis according to local guidelines if required by regulatory authorities or ethics committees (ECs).
  12. Patient has positive results at Screening for surface antigen (HBsAg), hepatitis B core antibody (HbsAqHBsAq), or antibody (HbsAqHBsAq) with positive HCV RNA polymerase chain reaction; or positive HIV serology at Screening.
  13. Patient has a helminth parasitic infection diagnosed within 24 weeks prior to the date of informed consent that has not been treated with, or has failed to respond to, standard of care therapy.
  14. Patient shows evidence of acute or chronic infection requiring treatment with antibacterials, antivirals, antifungals, antiparasitics, or antiprotozoals within 28 days of Screening, or significant viral infections within 28 days of Screening that may not have received antiviral treatment (eg, influenza receiving only symptomatic treatment).
  15. Patient receives live (attenuated) vaccinations within 7 days of Screening or plans to receive live (attenuated) vaccinations during the study.
  16. Patient has any disorder that is not stable in the opinion of the Investigator and may affect the safety of the patient throughout the study; influence the findings of the studies or their interpretations; or impede the patient's ability to complete the entire duration of study, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment.
  17. Patient has any abnormal findings in physical examination, vital signs, or safety lab tests during Screening/Run-in Period; or any significant medical history which, in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.
  18. Patient is being treated with immunosuppressive therapy or biologic therapy for disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis).
  19. Patient has a prolonged (QTc) interval (male > 450 milliseconds, female > 470 milliseconds) or tachyarrhythmia.
  20. Patient has any of the following laboratory abnormalities at Screening:

    • Eosinophils > 1500 cells/mmE3 or 1.5*10E9/L
    • \< 100000 cells/mmE3 or 100*10E9/L
    • Creatine phosphokinase (CPK) > 10 times the (ULN)
    • (ALT) > 2.5 times the ULN
    • Aspartate aminotransferase (AST) ≥ 2.5 times the ULN
    • > 2 times the ULN.
  21. Patient has a history of alcohol or drug abuse within 12 months of Screening.
  22. Patient has an allergy to L-histidine, trehalose, or Tween (polysorbate) 80 or a history of a systemic reaction, other than localized injection site reaction, to any biologic drug.
  23. Patient has a history of within 5 years prior to the Baseline Visit, with the following exceptions: patients with a history of completely treated carcinoma in situ of cervix and nonmetastatic squamous or basal cell carcinoma of the skin are allowed.
  24. Female patient is pregnant, planning to become pregnant, or is breastfeeding.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    CBP-201 Dose 1

    CBP-201 Dose 1 subcutaneous (SC) injection.

    Drug: CBP-201

  • Experimental
    CBP-201 Dose 2

    CBP-201 Dose 2 subcutaneous (SC) injection.

    Drug: CBP-201

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

Interventions

  • CBP-201 subcutaneous (SC) injection.

    Also known as: rademikibart

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Absolute change in prebronchodilator (trough) forced expiratory volume in the first second of expiration (FEV1)

    Absolute change from Baseline in prebronchodilator (trough) FEV1 at Week 12. To assess the efficacy of CBP-201 (Dose 1 and Dose 2) versus placebo in patients with moderate to severe persistent asthma with type 2 inflammation as measured by lung function improvements.

    Time frame: at Week 12

Secondary outcomes

  1. Absolute change in prebronchodilator (trough) FEV1

    Absolute change from Baseline in prebronchodilator (trough) FEV1 at Weeks 1, 2, 4, 8 and 24.

    Time frame: at Weeks 1, 2, 4, 8 and 24

  2. Percent change in prebronchodilator (trough) FEV1

    Percent change from Baseline in prebronchodilator (trough) FEV1 at Weeks 1, 2, 4, 8, 12 and 24.

    Time frame: at Weeks 1, 2, 4, 8, 12 and 24

  3. Change in other lung function measurements

    Change from Baseline in other lung function measurements \[percentage predicted FEV1, morning and evening peak expiratory flow (PEF)\].

    Time frame: From Baseline to Week 24

  4. Time to severe exacerbation and number of events

    Time to severe exacerbation and number of events during the 24 weeks Treatment Period.

    Time frame: From Baseline to Week 24

  5. Proportion of patients with ≥ 1 asthma exacerbation

    Proportion of patients with ≥ 1 asthma exacerbation during the 24 weeks Treatment Period.

    Time frame: From Baseline to Week 24

  6. Incidence, type and severity of Adverse Event (AE)

    Safety endpoints will be summarized by descriptive statistics and narratives where indicated by severity. Safety will be assessed on basis of AEs reported, including SAEs and AESIs.

    Time frame: From Baseline to Week 32

  7. Pharmacokinetics (Steady-state trough PK profile)

    Whole blood for plasma CBP-201 concentrations will be obtained and analyzed.

    Time frame: From Baseline to Week 32

07

Study locations

76 sites
  • Connect Investigative Site 154
    Tucson, Arizona 85704, United States
  • Connect Investigative Site 109
    Huntington Beach, California 92647, United States
  • Connect Investigative Site 143
    Huntington Beach, California 92647, United States
  • Connect Investigative Site 132
    Lancaster, California 93534, United States
  • Connect Investigative Site 125
    Mission Viejo, California 92691, United States
  • Connect Investigative Site 103
    San Jose, California 95117, United States
  • Connect Investigative Site 161
    Hialeah, Florida 33012, United States
  • Connect Investigative Site 114
    Hollywood, Florida 33021, United States
  • Connect Investigative Site 142
    Leesburg, Florida 34748, United States
  • Connect Investigative Site 165
    Miami Gardens, Florida 33014, United States
  • Connect Investigative Site 110
    Miami Lakes, Florida 33014, United States
  • Connect Investigative Site 104
    Miami, Florida 33126, United States
  • Connect Investigative Site 166
    Miami, Florida 33145, United States
  • Connect Investigative Site 118
    Miami, Florida 33155, United States
  • Connect Investigative Site 162
    Miami, Florida 33155, United States
  • Connect Investigative Site 163
    Miami, Florida 33174, United States
  • Connect Investigative Site 164
    Miami, Florida 33174, United States
  • Connect Investigative Site 105
    Miami, Florida 33176, United States
  • Connect Investigative Site 123
    Winter Park, Florida 32789, United States
  • Connect Investigative Site 124
    Bangor, Maine 04401, United States
  • Connect Investigative Site 120
    White Marsh, Maryland 21162, United States
  • Connect Investigative Site 146
    West Bloomfield, Michigan 48322, United States
  • Connect Investigative Site 112
    Saint Louis, Missouri 63141, United States
  • Connect Investigative Site 119
    Bellevue, Nebraska 78759, United States
  • Connect Investigative Site 144
    North Las Vegas, Nevada 89030, United States
  • Connect Investigative Site 111
    Princeton, New Jersey 08540, United States
  • Connect Investigative Site 117
    Buffalo, New York 14201, United States
  • Connect Investigative Site 153
    New York, New York 10036, United States
  • Connect Investigative Site 122
    Winston-Salem, North Carolina 27104, United States
  • Connect Investigative Site 136
    Cincinnati, Ohio 45236, United States
  • Connect Investigative Site 147
    Toledo, Ohio 43617, United States
  • Connect Investigative Site 107
    Edmond, Oklahoma 73034, United States
  • Connect Investigative Site 149
    Oklahoma City, Oklahoma 73120, United States
  • Connect Investigative Site 129
    Warwick, Rhode Island 02886, United States
  • Connect Investigative Site 116
    Austin, Texas 78759, United States
  • Connect Investigative Site 102
    Boerne, Texas 78006, United States
  • Connect Investigative Site 121
    Dallas, Texas 75231, United States
  • Connect Investigative Site 108
    El Paso, Texas 79903, United States
  • Connect Investigative Site 150
    Katy, Texas 77450, United States
  • Connect Investigative Site 206
    Bengbu, Anhui 233000, China
  • Connect Investigative Site 201
    Beijing, Beijing 100029, China
  • Connect Investigative Site 216
    Beijing, Beijing 100039, China
  • Connect Investigative Site 209
    Beijing, Beijing 100730, China
  • Connect Investigative Site 215
    Beijing, Beijing 101100, China
  • Connect Investigative Site 203
    Guangzhou, Guangdong 510080, China
  • Connect Investigative Site 211
    Luoyang, Henan 471003, China
  • Connect Investigative Site 213
    Wuhan, Hubei 430000, China
  • Connect Investigative Site 202
    Changsha, Hunan 410013, China
  • Connect Investigative Site 204
    Baotou, Inner Mongolia 014000, China
  • Connect Investigative Site 214
    Baotou, Inner Mongolia 14010, China
  • Connect Investigative Site 210
    Hohhot, Inner Mongolia 010050, China
  • Connect Investigative Site 205
    Wuxi, Jiangsu 214023, China
  • Connect Investigative Site 208
    Yangzhou, Jiangsu 225007, China
  • Connect Investigative Site 212
    Changchun, Jilin 130021, China
  • Connect Investigative Site 220
    Shenyang, Liaoning 11004, China
  • Connect Investigative Site 207
    Shanghai, Shanghai 200025, China
  • Connect Investigative Site 218
    Shanghai, Shanghai 200433, China
  • Connect Investigative Site 221
    Taiyuan, Shanxi 030001, China
  • Connect Investigative Site 222
    Taiyuan, Shanxi 030032, China
  • Connect Investigative Site 224
    Ürümqi, Xinjiang 830054, China
  • Connect Investigative Site 217
    Ningbo, Zhejiang 315046, China
  • Connect Investigative Site 304
    Püspökladány, Hajdú-Bihar 4150, Hungary
  • Connect Investigative Site 303
    Szombathely, Vas 9700, Hungary
  • Connect Investigative Site 505
    Incheon, Gyeonggi 21565, Korea, Republic of
  • Connect Investigative Site 503
    Seongnam-si, Gyeonggi 13496, Korea, Republic of
  • Connect Investigative Site 501
    Seoul, Seoul Teugbyeolsi 03080, Korea, Republic of
  • Connect Investigative Site 502
    Seoul, Seoul Teugbyeolsi 03722, Korea, Republic of
  • Connect Investigative Site 403
    Lubin, Dolnoslaskie 59-300, Poland
  • Connect Investigative Site 408
    Wrocław, Dolnoslaskie 53-301, Poland
  • Connect Investigative Site 406
    Skierniewice, Lódzkie 96-100, Poland
  • Connect Investigative Site 402
    Kraków, Malopolskie 30-033, Poland
  • Connect Investigative Site 401
    Kraków, Malopolskie 31-559, Poland
  • Connect Investigative Site 404
    Białystok, Podlaskie 15-010, Poland
  • Connect Investigative Site 405
    Białystok, Podlaskie 15-010, Poland
  • Connect Investigative Site 410
    Częstochowa, Świętokrzyskie 42-200, Poland
  • Connect Investigative Site 407
    Skarżysko-Kamienna, Świętokrzyskie 26-110, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Aug 2023, 26 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 26 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Feb 26, 2021
StartActual
May 11, 2021
Primary completionActual
Aug 5, 2023
CompletionActual
Sep 28, 2023
Last update
Mar 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04773678
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
May 11, 2021
Primary completion
Aug 5, 2023
Completion
Sep 28, 2023
Last update
Mar 29, 2024

Study contacts

Suzhou Connect
study director · Connect Biopharm LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion